Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Clinical perspectives of PARP inhibitors
Grazia Graziani
, Csaba Szabó
Research output
:
Contribution to journal
›
Article
›
peer-review
141
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical perspectives of PARP inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
PARP Inhibitor (PARPi)
100%
Clinical Perspective
100%
Poly(ADP-ribose) Polymerase
71%
Antitumor Agents
28%
Potential Risk
14%
DNA Repair
14%
Neurodegeneration
14%
Cardiovascular Disease
14%
Human Disease
14%
Clinical Trials
14%
Pharmacological Inhibitors
14%
Inflammatory Cells
14%
Therapeutic Effect
14%
Clinical Outcomes
14%
Clinical High Risk
14%
Cell Injury
14%
Life-limiting Conditions
14%
Clinical Application
14%
Severe Disease
14%
Patient with Tumor
14%
Experimental Therapeutics
14%
Diabetes Complications
14%
Inflammatory Diseases
14%
Organ Damage
14%
Cytotoxicity
14%
Poor Prognosis
14%
Long-term Adverse Effects
14%
Ischemia-reperfusion Injury
14%
Myocardial Infarction
14%
Cardiopulmonary Bypass
14%
Chronic Use
14%
Neuroinflammation
14%
Thoracic Aortic Surgery
14%
Temozolomide
14%
Clinical Development
14%
Double-edged Sword
14%
Clinical Potential
14%
Additional Indications
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
71%
Diseases
42%
Clinical Trial
14%
Cytoprotective Agent
14%
Ischemia
14%
Nerve Degeneration
14%
Therapeutic Effect
14%
Inflammatory Disease
14%
Diabetic Complication
14%
Organ Injury
14%
Heart Infarction
14%
Nervous System Inflammation
14%
Aneurysm
14%
Temozolomide
14%
Cerebrovascular Accident
14%
Cytotoxicity
14%
Cardiovascular Disease
14%
Side Effect
14%